This Leading Pharma Company Has Grown Its Dividend 70% Since 2020

FomoAnxiety · 2026-03-27T15:12:43+00:00

Abbott Laboratories has raised its dividend for the 54th consecutive year, now at $0.63 per share, reflecting a 70% growth since 2020. Despite a declining stock price, analysts maintain a Strong Buy rating, highlighting its strong fundamentals and growing dividend.

FomoAnxiety

2026-03-27 15:12:43

Abstract generation in progress

Investors on the hunt for a fast-growing dividends need look no further than Abbott Laboratories ABT -0.13% ▼ .

Claim 30% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

In December of last year, Abbott increased its dividend by 6.8% to $0.63 per share. It was the 54th year in a row that Abbott has increased its dividend. Since 2020, the dividend has grown by 70%, faster than just about any other dividend on offer.

Currently, ABT stock has a dividend yield of 2.42%, which is about double the average dividend yield among stocks listed in the benchmark S&P 500 index. Management at Abbott Labs continues to prioritize the dividend and rewarding its shareholders.

ABT Stock Performance

The rapid dividend growth at Abbott comes as the company’s stock has struggled. Over the last five years, the company’s share price has declined 15%. So far in 2026, the shares are down 16%. The main reason for the decline has been its baby-formula business.

Abbott has increasingly raised the price of its baby formula as manufacturing costs have risen and due to tariffs, hurting sales in the process. Most recently, Abbott reported that its nutrition sales were $1.9 billion, which was below analyst expectations. However, overall Abbott’s financial results have been strong and the company’s main business making medical devices remains solid.

While shareholders wait for ABT stock to recover, they can comfort themselves with the growing dividend.

Is ABT Stock a Buy?

Abbott Laboratories stock has a consensus Strong Buy rating among 15 analysts. That rating is based on 14 Buy and one Hold recommendations issued in the last three months. The average ABT price target of $137.14 implies 31% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes